

**Abstract of the Disclosure**

The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression *in vivo*. One example of an ITAM/ITIM receptor pair is Fc $\epsilon$ RI and HM18, and another is Fc $\epsilon$ RI and Fc $\gamma$ RII. Cross-linking of these receptors with a bispecific molecule of the invention would lead to inhibition of the release of allergic mediators and amelioration of the symptoms of allergic diseases. Other diseases can be ameliorated by cross-linking ITIM/ITAM receptor pairs.